{
  "trial_id": "NCT02041429",
  "trial_group": "cancer",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, gender, ECOG performance status, life expectancy, leukocyte count, absolute neutrophil count, platelet count, total bilirubin level, AST (SGOT) level, ALT (SGPT) level, creatinine level, creatinine clearance, prior chemotherapy treatments, presence of brain metastases, history of allergic reactions, use of CYP3A4 inhibitors, corticosteroid use, presence of intercurrent illness, pregnancy status, breastfeeding status, history of other malignancies, presence of malabsorption syndrome, prior chemotherapy or radiation.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "gender"
        ],
        [
          "Eastern Cooperative Oncology Group Performance Status",
          "ECOG performance status"
        ],
        [
          "Prior Lines of Chemotherapy for Metastatic Breast Cancer",
          "prior chemotherapy treatments"
        ],
        [
          "Measurable Disease Present at Baseline",
          "presence of brain metastases"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Region of Enrollment",
        "Received Prior Endocrine Therapy for Metastatic Breast Cancer",
        "Received Prior Adjuvant Chemotherapy",
        "Received Prior Adjuvant Endocrine Therapy",
        "Estrogen and/or Progesterone Receptor Positive",
        "Triple Negative (Estrogen, Progesterone, Tyrosine-Protein Kinase erbB-2 receptors negative)"
      ],
      "remaining_candidate_features": [
        "life expectancy",
        "leukocyte count",
        "absolute neutrophil count",
        "platelet count",
        "total bilirubin level",
        "AST (SGOT) level",
        "ALT (SGPT) level",
        "creatinine level",
        "creatinine clearance",
        "history of allergic reactions",
        "use of CYP3A4 inhibitors",
        "corticosteroid use",
        "presence of intercurrent illness",
        "pregnancy status",
        "breastfeeding status",
        "history of other malignancies",
        "presence of malabsorption syndrome",
        "prior chemotherapy or radiation"
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, ECOG performance status, Leukocyte count, Absolute neutrophil count, Platelet count, Total bilirubin, AST (SGOT), ALT (SGPT), Creatinine, Life expectancy, Prior chemotherapy, Metastatic status,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Eastern Cooperative Oncology Group Performance Status",
          "ECOG performance status"
        ],
        [
          "Prior Lines of Chemotherapy for Metastatic Breast Cancer",
          "Prior chemotherapy"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Region of Enrollment",
        "Received Prior Endocrine Therapy for Metastatic Breast Cancer",
        "Received Prior Adjuvant Chemotherapy",
        "Received Prior Adjuvant Endocrine Therapy",
        "Estrogen and/or Progesterone Receptor Positive",
        "Triple Negative (Estrogen, Progesterone, Tyrosine-Protein Kinase erbB-2 receptors negative)",
        "Measurable Disease Present at Baseline"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Leukocyte count",
        "Absolute neutrophil count",
        "Platelet count",
        "Total bilirubin",
        "AST (SGOT)",
        "ALT (SGPT)",
        "Creatinine",
        "Life expectancy",
        "Metastatic status"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, ECOG Performance Status, Life Expectancy, Leukocytes, Absolute Neutrophil Count, Platelets, Total Bilirubin, AST (SGOT), ALT (SGPT), Creatinine, Histologically Confirmed Breast Cancer, Metastatic or Unresectable Disease, Prior Chemotherapies for Advanced Disease, Measurable or Evaluable Disease.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Eastern Cooperative Oncology Group Performance Status",
          "ECOG Performance Status"
        ],
        [
          "Prior Lines of Chemotherapy for Metastatic Breast Cancer",
          "Prior Chemotherapies for Advanced Disease"
        ],
        [
          "Measurable Disease Present at Baseline",
          "Measurable or Evaluable Disease"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Region of Enrollment",
        "Received Prior Endocrine Therapy for Metastatic Breast Cancer",
        "Received Prior Adjuvant Chemotherapy",
        "Received Prior Adjuvant Endocrine Therapy",
        "Estrogen and/or Progesterone Receptor Positive",
        "Triple Negative (Estrogen, Progesterone, Tyrosine-Protein Kinase erbB-2 receptors negative)"
      ],
      "remaining_candidate_features": [
        "Race/Ethnicity",
        "Region of Enrollment",
        "Life Expectancy",
        "Leukocytes",
        "Absolute Neutrophil Count",
        "Platelets",
        "Total Bilirubin",
        "AST (SGOT)",
        "ALT (SGPT)",
        "Creatinine",
        "Histologically Confirmed Breast Cancer",
        "Metastatic or Unresectable Disease"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, ECOG performance status, life expectancy, histological type of breast cancer, number of prior chemotherapies, presence of measurable or evaluable disease, leukocyte count, absolute neutrophil count, platelet count, total bilirubin, AST (SGOT), ALT (SGPT), creatinine, creatinine clearance.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ],
        [
          "Eastern Cooperative Oncology Group Performance Status",
          "ECOG performance status"
        ],
        [
          "Prior Lines of Chemotherapy for Metastatic Breast Cancer",
          "number of prior chemotherapies"
        ],
        [
          "Measurable Disease Present at Baseline",
          "presence of measurable or evaluable disease"
        ]
      ],
      "remaining_reference_features": [
        "Male",
        "Region of Enrollment",
        "Received Prior Endocrine Therapy for Metastatic Breast Cancer",
        "Received Prior Adjuvant Chemotherapy",
        "Received Prior Adjuvant Endocrine Therapy",
        "Estrogen and/or Progesterone Receptor Positive",
        "Triple Negative (Estrogen, Progesterone, Tyrosine-Protein Kinase erbB-2 receptors negative)"
      ],
      "remaining_candidate_features": [
        "life expectancy",
        "histological type of breast cancer",
        "leukocyte count",
        "absolute neutrophil count",
        "platelet count",
        "total bilirubin",
        "AST (SGOT)",
        "ALT (SGPT)",
        "creatinine",
        "creatinine clearance."
      ]
    }
  }
}